Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with OAB who have been treated with tolterodine tartrate extended release for at least 4 weeks immediately preceding entry into the study, and wish to switch to solifenacin succinate due to lack of sufficient improvement in urgency episodes.~* Previous non-drug treatment of OAB is allowed if it has been established at least 4 weeks prior to Screening and is continued throughout the study.~* At least 3 urinary urgency episodes/24 hours while receiving tolterodine tartrate extended release documented in a 3-day patient diary in the pre-washout assessments on tolterodine tartrate extended release with or without urge incontinence described as OAB syndrome.~* Prior to treatment with tolterodine tartrate extended release, patients must have had OAB syndrome for 3 or more months.~Exclusion Criteria:~* Previous treatment with darifenacin~* Treatment with tolterodine tartrate extended release for less than 4 weeks prior to enrollment in the study.~* Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor as determined by the investigator.~* Evidence of a urinary tract infection; chronic inflammation such as interstitial cystitis and bladder stones.~* Clinically significant outflow obstruction as determined by the Investigator~* Uncontrolled narrow angle glaucoma, urinary or gastric retention.~* All patients with severe renal or hepatic impairment will be excluded~* Patients with chronic severe constipation or history of diagnosed gastrointestinal obstructive disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).